Summary

Global Blood Product Market was valued at USD 44.09 Billion in 2024 and is expected to reach USD 62.62 Billion by 2030 with a CAGR of 5.98% during the forecast period. The global blood product market is primarily driven by the increasing prevalence of chronic diseases, bleeding disorders, and immune deficiencies that require blood products such as plasma, albumin, clotting factors, and immunoglobulins. The aging population globally is also contributing to a rise in demand for blood-based therapies. Advancements in medical treatments, surgical procedures, and trauma care, which often require blood transfusions, are fuelling market growth. Increased awareness and the growing adoption of blood product therapies for conditions like hemophilia, autoimmune disorders, and burn injuries are major factors. The expansion of healthcare infrastructure, particularly in emerging markets, and regulatory advancements ensuring safety and quality in blood product use are also key drivers in the market's expansion.
Key Market Drivers
Increasing Prevalence of Chronic Diseases
The increasing prevalence of chronic diseases has become one of the primary drivers of the global blood product market. Conditions such as hemophilia, autoimmune disorders, immune deficiencies, liver diseases, and kidney dysfunction require regular medical interventions, many of which involve the use of blood products. According to Centers for Disease Control and Prevention, an estimated 33,000 males in the United States are living with hemophilia, a condition characterized by spontaneous (unexplained) bleeding and excessive bleeding after injury. This often includes recurrent bleeding within joints, which can lead to chronic joint disease. While bleeding symptoms in females with hemophilia tend to be milder compared to males, studies have shown that females with hemophilia still experience reduced joint range of motion compared to females without a bleeding disorder.
For example, hemophilia patients require clotting factor concentrates to manage bleeding episodes, and immune deficiency disorders are treated with immunoglobulin therapies derived from blood plasma. The rise in chronic disease rates worldwide is largely due to lifestyle factors, such as poor diet, sedentary behavior, and an aging population. As these diseases become more widespread, the need for blood-derived treatments is growing, leading to an increase in demand for essential blood products.
Aging Population and Associated Health Conditions
The aging population is another significant factor driving the demand for blood products. As the global population ages, there is an increased prevalence of age-related health issues such as cardiovascular diseases, cancer, diabetes, neurological disorders, and renal failure. Countries around the world are confronted with significant challenges in preparing their health and social systems to effectively address the implications of an aging population. According to WHO, by 2050, 80% of older individuals will reside in low- and middle-income countries, and the rate of population aging is accelerating rapidly compared to previous generations. In fact, by 2020, the number of people aged 60 and older surpassed the number of children under the age of 5.
Older individuals are also more likely to experience trauma or need major surgeries, which often require the transfusion of blood products like red blood cells, plasma, and platelets. The aging demographic, particularly in developed nations, results in a higher incidence of chronic illnesses that require ongoing medical treatments. This has led to a surge in the demand for blood-derived therapies, such as albumin and clotting factor concentrates, which are used to manage a variety of medical conditions common in elderly patients.
Improved Blood Collection and Processing Technologies
Technological advancements in blood collection and processing technologies have greatly enhanced the efficiency and safety of blood product production. The introduction of automated blood collection systems has streamlined the process, reducing the time and labor required to collect blood and plasma. Fractionation technology has enabled the separation and purification of plasma into its essential components, allowing for targeted therapies to be derived from the same blood donation. This has reduced wastage and increased the overall yield of usable blood products. Advancements in storage technology have made it easier to preserve blood components for extended periods, ensuring they remain viable and ready for use when needed. These innovations have made blood collection and processing more cost-effective and have improved the supply of plasma-derived therapies, making them more accessible to patients.
Increased Awareness and Blood Donation Initiatives
Growing public awareness of the importance of blood donation and the essential role of blood products in saving lives has also contributed to the expansion of the market. Health campaigns and initiatives to encourage blood donation have led to increased blood donations globally. As a result, plasma collection centers and blood banks are receiving a higher volume of donations, ensuring a steady supply of raw materials needed for blood product manufacturing. In 2024, the Singapore Red Cross (SRC) has launched a new initiative aimed at engaging 500 young people aged 16 to 25 over the next five years. The organization also plans to increase the proportion of youth donors in its program to 25% by 2030, up from the current 15%. A study by the Health Sciences Authority (HSA) revealed that individuals aged 60 and above account for 60% of blood usage, as the likelihood of needing a blood transfusion increases with age due to a higher susceptibility to anemia and the development of multiple comorbidities.
The global demand for blood products is thus met through a combination of effective donor recruitment and better donor retention strategies, helping ensure that essential blood products are available when needed. Increased awareness has created a more robust blood donation infrastructure, which supports the market's growth.
Growing Investment in Healthcare Infrastructure
Healthcare infrastructure development, particularly in emerging economies, has been a crucial driver of the blood product market. As countries in Asia Pacific, Africa, and South America continue to invest in medical facilities, hospitals, and blood banks, there is a growing need for blood products to meet the healthcare demands of expanding populations. Governments and private sector companies are making substantial investments in modern medical equipment and blood storage technologies, which are crucial for supporting large-scale blood collection and transfusion operations. These investments in healthcare systems are enabling emerging markets to increase their production, collection, and processing capacity for blood products, which in turn supports the global market.
Key Market Challenges
Blood Product Supply Shortages
One of the primary challenges faced by the blood product market is supply shortages. The collection of blood and plasma is heavily dependent on voluntary donations, which can be inconsistent and unpredictable. In some regions, particularly in developing countries, there is a lack of sufficient donation campaigns and donor awareness, leading to gaps in supply. There are seasonal fluctuations in donation rates, with fewer donations occurring during certain times of the year, such as holidays. This inconsistency in blood and plasma donations can result in shortages of critical blood products, creating a bottleneck for production and distribution. These supply challenges require continuous efforts in donor recruitment and public education to ensure a stable supply of blood products.
High Costs of Blood Product Manufacturing
The manufacturing of blood products, particularly plasma-derived therapies, is a costly process. The fractionation of plasma into its components, such as albumin, immunoglobulins, and clotting factors, requires advanced technologies and highly specialized equipment. The storage and transportation of blood products must meet strict regulatory standards, which further increases the cost. Plasma-derived products often carry premium pricing due to the complexity of the production process, and this can make access to these therapies difficult, especially in low-income regions. The high costs of blood product production are a barrier for many healthcare systems, which struggle to provide affordable access to essential treatments. This issue requires efforts to reduce manufacturing costs through innovative technologies and efficient processes while maintaining high standards of safety and efficacy.
Key Market Trends
Trauma and Surgical Procedures
Trauma cases and surgical procedures are major contributors to the growth of the blood product market. As global traffic accidents, workplace injuries, and other trauma-related incidents increase, there is a greater need for blood transfusions to stabilize patients. Trauma patients often require red blood cells for blood loss management and plasma for clotting support. Similarly, major surgeries, such as cardiac, orthopedic, and cancer surgeries, frequently require blood transfusions to replace lost blood and aid recovery. As surgical procedures become more common, especially with the rising number of complex surgeries performed worldwide, the need for blood products has significantly increased. The growing incidence of trauma and surgical operations is directly linked to the increase in demand for blood products, making this one of the key drivers of the market.
Advancements in Blood Product Therapies
Innovation in the development of blood product therapies is another crucial factor driving the market's expansion. The field of plasma fractionation has evolved to extract a wider range of therapeutic proteins, including immunoglobulins, albumin, and clotting factors, which are essential for treating various medical conditions. For instance, immunoglobulins are used to treat autoimmune diseases, and albumin is used in critical care settings for patients with burns or shock. In March 2024, BD (Becton, Dickinson, and Company) launched the BD Vacutainer® UltraTouchTM Push Button Blood Collection Set in India, aiming to reduce patient pain and discomfort while enhancing the likelihood of a successful single-prick blood collection.
The development of synthetic blood products and next-generation treatments using biotechnology has expanded the scope of blood-derived therapies. The growing ability to tailor blood products for specific diseases and patients has enhanced the effectiveness of treatments, driving both market growth and increasing patient demand for these specialized products.
Segmental Insights
Type Insights
Based on the Type, Red Blood Cells (RBCs) dominated the global blood product market in terms of both volume and demand. RBCs are essential for oxygen transport throughout the body, and they play a critical role in managing conditions like anemia, hemorrhagic shock, surgical blood loss, and trauma. The need for RBCs is widespread due to their broad application in clinical settings such as emergency medicine, trauma care, surgery, and oncology. RBC transfusions are crucial for patients undergoing major surgeries, cancer treatments, or managing severe blood loss, making them the most commonly used blood product globally.
The demand for Red Blood Cells is consistently high across hospitals and healthcare systems worldwide. The global trauma burden, including traffic accidents, natural disasters, and workplace injuries, has contributed to the elevated need for blood transfusions. Surgical procedures, especially in cardiothoracic and orthopedic surgeries, often result in significant blood loss, requiring immediate RBC transfusions. Conditions like sickle cell anemia, thalassemia, and chronic kidney disease further contribute to the demand, as patients with these diseases often require regular RBC transfusions to manage their health.
Another significant factor driving the dominance of RBCs is the advancements in blood storage and preservation technologies. The ability to store red blood cells for up to 42 days at controlled temperatures has made it easier for healthcare facilities to maintain an adequate supply, ensuring that patients receive timely transfusions when necessary. RBCs have become the go-to product for treating acute blood loss, and this widespread application has established them as the leading blood product in terms of demand.
Application Insights
Based on the Application segment, Hospitals was the dominant players in the global blood product market. While blood stations, also known as blood banks or plasma collection centers, are essential for the collection and initial processing of blood, hospitals are where the majority of blood products are utilized for patient care. The primary reason for this dominance is the direct role that hospitals play in patient treatment. Hospitals are the centers of medical emergencies, surgeries, and long-term care, where blood products like red blood cells, platelets, fresh frozen plasma, and other blood components are crucial for life-saving procedures.
Hospitals across the world are the main consumers of blood products, particularly in high-demand clinical scenarios such as trauma care, surgical operations, and emergency medical situations. Trauma cases, such as accidents, burns, and natural disasters, require immediate transfusions of red blood cells and plasma to stabilize patients. Hospitals are also where surgical procedures of all types are performed, from routine operations to complex surgeries, such as cardiac bypass, orthopedic procedures, and organ transplants. These surgeries often result in blood loss, making blood transfusions necessary to support the patient’s recovery. Hospitals manage long-term care patients, including those with cancer, anemia, kidney disease, and liver conditions, who require regular blood transfusions to manage their medical conditions.
The growing number of surgical operations and trauma cases worldwide has significantly contributed to the increasing demand for blood products in hospitals. Hemorrhagic shock, which results from severe blood loss due to injuries or surgeries, is a major concern in emergency care settings. Hospitals are equipped with blood banks that ensure an adequate supply of blood products is always available for transfusion. Hospitals with specialized departments in oncology, cardiology, neurology, and neonatology often require specific blood products for treatments like chemotherapy, heart surgeries, and the management of premature infants, further driving the demand for blood products in these institutions.
Regional Insights
North America was the dominant region in the global blood product market. The United States, in particular, plays a significant role in driving this dominance, due to its advanced healthcare infrastructure, high demand for blood products, and ongoing innovations in the field. The market in North America benefits from strong support systems, including blood banks, plasma collection centers, and emergency healthcare services that ensure a continuous supply of blood products such as red blood cells, platelets, fresh frozen plasma, and other critical components. Hospitals and healthcare institutions in the region consume a significant volume of these products due to their involvement in surgical procedures, trauma care, cancer treatments, and emergency medicine.
The United States alone accounts for a large portion of the market share in North America. The country has an extensive network of blood collection and transfusion services, such as the American Red Cross, which ensures that hospitals are consistently stocked with essential blood products. The strong healthcare infrastructure and advanced medical technology available in the region also facilitate the efficient processing, storage, and distribution of blood products. North American countries like Canada also play a key role in the market, with well-established blood collection systems and increasing efforts to promote plasma donation, further boosting the availability of blood products.
North America's dominance in the blood product market is also driven by a high number of trauma cases, emergency surgeries, and an aging population that requires frequent blood transfusions. The rising incidence of chronic diseases, such as cancer, anemia, and kidney disorders, has led to an increased demand for blood products in treatment regimens. The demand for plasma-derived products, like albumin and immunoglobulins, has also been rising in North America, owing to their application in treating various medical conditions like immune disorders, liver diseases, and respiratory illnesses.
The strong regulatory frameworks in North America also contribute to the region's leadership in the blood product market. The Food and Drug Administration (FDA) and other regulatory bodies have established stringent safety standards for blood collection, processing, and transfusion, ensuring that blood products are safe for patient use. This regulatory oversight has helped build trust in the safety and efficacy of blood products in the region, further encouraging their use in hospitals and clinics.
In addition to healthcare services, North America's blood product market is supported by ongoing advancements in medical technologies. Innovations in blood processing technologies, such as automated systems for blood typing, separation, and storage, have improved the efficiency and safety of blood transfusions. The growing use of artificial intelligence and machine learning in the management of blood supplies has also contributed to the region's market growth. These advancements have streamlined blood collection processes, reduced the risk of human error, and improved overall patient outcomes.
Key Market Players
• CSL Limited
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Grifols, S.A.
• Kedrion S.p.A
• Hualan Biological Vaccine Inc.
• Mitsubishi Tanabe Pharma Corporation
• Baxter International Inc.
• Versiti, Inc.
• Bio Products Laboratory Ltd.
Report Scope:
In this report, the Global Blood Product Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Blood Product Market, By Type:
o Red Blood Cells
o Platelets
o Fresh Frozen Plasma
o White Blood Cells
o Others
• Blood Product Market, By Application:
o Blood Station
o Hospitals
o Others
• Blood Product Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia-Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Blood Product Market.
Available Customizations:
Global Blood Product market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Blood Product Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Red Blood Cells, Platelets, Fresh Frozen Plasma, White Blood Cells, and Others)
5.2.2. By Application (Blood Station, Hospitals and Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Blood Product Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Application
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Blood Product Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Application
6.3.2. Canada Blood Product Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Application
6.3.3. Mexico Blood Product Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Application
7. Europe Blood Product Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Application
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Blood Product Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Application
7.3.2. United Kingdom Blood Product Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Application
7.3.3. Italy Blood Product Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Application
7.3.4. France Blood Product Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Application
7.3.5. Spain Blood Product Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Application
8. Asia-Pacific Blood Product Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Application
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Blood Product Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Application
8.3.2. India Blood Product Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Application
8.3.3. Japan Blood Product Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Application
8.3.4. South Korea Blood Product Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Application
8.3.5. Australia Blood Product Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Application
9. South America Blood Product Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Application
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Blood Product Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Application
9.3.2. Argentina Blood Product Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Application
9.3.3. Colombia Blood Product Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Application
10. Middle East and Africa Blood Product Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Application
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Blood Product Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Application
10.3.2. Saudi Arabia Blood Product Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Application
10.3.3. UAE Blood Product Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. CSL Limited
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Financials (As Reported)
14.1.5. Recent Developments
14.1.6. Key Personnel Details
14.1.7. SWOT Analysis
14.2. Takeda Pharmaceutical Company Limited
14.3. Octapharma AG
14.4. Grifols, S.A.
14.5. Kedrion S.p.A
14.6. Hualan Biological Vaccine Inc.
14.7. Mitsubishi Tanabe Pharma Corporation
14.8. Baxter International Inc.
14.9. Versiti, Inc.
14.10. Bio Products Laboratory Ltd.
15. Strategic Recommendations
16. About Us & Disclaimer